報價延遲最少15分鐘:2025/05/12 10:50 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.135 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.11/-0.56
|
|
企業價值
712.12M
|
| 資產負債 |
|
每股賬面淨值
1.37
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.87M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/12 10:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |